Pulmonx's Zephyr endobronchial valve shows promise for patients with severe emphysema
As it awaits a decision from the FDA on its PMA, Pulmonx Corp. touted positive one-year results from the U.S. LIBERATE pivotal trial of the Zephyr endobronchial valve for severe emphysema, including statistically significant reduction in the rate of respiratory failure in patients receiving the device. If approved, the therapy would offer a new choice for patients with limited options and who experience a poor quality of life.
CBO sees $1T deficit in 2020 as spending on Medicare spikes
The Congressional Budget Office (CBO) shone a glaring spotlight on the state of the U.S. economy with a report that predicts that the federal budget deficit will reach $1 trillion in 2020 on its way to a deficit of more than $1.5 trillion eight years later. Perhaps even more disturbing for makers of drugs and devices is that Medicare spending has resumed its robust growth rate now that the recession is over, and may double to $1.5 trillion in 2028, roughly the same number as the overall budget deficit in 2028.
Personalized medicine: Some progress but not there yet
CAMBRIDGE, U.K. "I have trained a large dog to bite anyone who says the words 'personalized medicine.' We are a long way from that." So said George Poste, chief scientist at Complex Adaptive Systems and professor of health innovation at Arizona State University, opening a discussion on the state of play in the field, at the Gap Summit in Cambridge. That is not to say there has been no progress in personalization in the 20 years that Poste has been talking about and been involved in this upcoming new era of medicine.